TLR4调节simvastatin对HDL胆固醇和血糖控制的影响
1Division of Endocrinology, Diabetes and Nutrition, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD, United States.
Frontiers in pharmacology
|February 2, 2026
概括
静止剂的时间影响高血压和葡萄糖代谢,食阶段的服用通过LPS-TLR4信号改善了葡萄糖控制. 这表明,将他类药物治疗与营养状况对齐可能会优化结果并减少副作用.
科学领域:
- 代谢调节 代谢调节 代谢调节
- 脂质代谢 脂质代谢 是一种
- 葡萄糖的恒常性是葡萄糖的恒常性.
背景情况:
- 类药物通过抑制HMG-CoA减少酶来降低LDL胆固醇,但它们的疗效和副作用 (如失糖症) 与胆固醇生物合成途径有关.
- 食-禁食周期,而不是昼夜钟,主要驱动肝脏SREBP活动和脂质生成.
- 在养状态下发生的代谢内毒素 (LPS-TLR4轴) 影响SREBP,LXR和PPARα信号,与他类药物对脂质和葡萄糖代谢的作用相互作用.
研究的目的:
- 调查相对于食禁食周期和LPS-TLR4信号传递的simvastatin时间如何影响小鼠的代谢结果.
- 阐明LPS-TLR4信号调节他类药物对脂质和葡萄糖代谢影响的机制.
主要方法:
- 在禁食或食阶段,向小鼠注射了simvastatin.
- 使用了代谢表型,肝转录和生化分析.
- 在缺乏托尔类受体4 (TLR4) 的小鼠中重复研究,以评估代谢性内毒性病的作用.
主要成果:
- 禁食阶段的simvastatin增加了HDL胆固醇,但影响了葡萄糖平衡.
- 食阶段的simvastatin降低了HDL胆固醇,同时改善了葡萄糖耐受性和胰岛素敏感性.
- LPS-TLR4信号调解了食阶段simvastatin的有益葡萄糖效应,而TLR4缺乏消除了这些结果.
结论:
- 相对于食和禁食,西姆瓦斯塔丁的时间对HDL和葡萄糖代谢产生相反的影响.
- 食诱导的LPS-TLR4信号对于这些不同的代谢结果至关重要.
- 将他类药物治疗与营养状况对齐,并针对LPS-TLR4-SREBP/LXR/PPARα轴,可以优化他类药物治疗并减轻失糖症.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.9K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.9K
Cholesterol: Significance and Regulation
2.0K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
2.0K
Pharmacogenomics: Identification of New Drug Targets
94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
908
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
908
Dipeptidyl Peptidase 4 Inhibitors
1.1K
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K
Atherosclerosis III: Management
603
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
603


